Brianna Costales

Brianna Costales
University of Florida | UF · Department of Pharmaceutical Outcomes and Policy

Bachelor of Science
PhD Candidate interested in pharmacoepdimiology, CNS therapeutics, and mental health outcomes

About

11
Publications
442
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
33
Citations

Publications

Publications (11)
Article
Objective/background Restless legs syndrome (RLS) is a complex condition associated with circadian rhythm that disrupts sleep and can cause multisystemic consequences. This study assesses pharmacotherapy treatment initiation, estimates annual treatment prevalence, and assesses treatment patterns for early-onset idiopathic RLS. Methods We used the...
Article
Full-text available
Background Little is known about the clinical training or practice experiences among physicians who certify patients for medical marijuana. The objective of this study was to determine information sources, factors influencing recommendations, clinical practices in patient assessment, communications, and recommendations, and priority areas for addit...
Article
Objective: Gabapentin is widely prescribed off label in medical practice, including psychiatry. The U.S. Food and Drug Administration (FDA) warned of risks associated with gabapentin combined with central nervous system depressant (CNS-D) drugs, which are commonly prescribed in psychiatric treatment. This study examined off-label outpatient gabape...
Article
Full-text available
In 2017, a National Academies of Sciences, Engineering, and Medicine (NASEM) report comprehensively evaluated the body of evidence regarding cannabis health effects through the year 2016. The objectives of this study are to identify and map the most recently (2016–2019) published literature across approved conditions for medical cannabis and to eva...
Article
Full-text available
Initial legalization of medical marijuana (MM) in Florida required providers to submit initial and follow-up treatment plan forms to the University of Florida to support research on MM safety and efficacy. This study retrospectively analyzed all treatment plan forms submitted between program inception (August 2016) through July 2017 and describes e...
Article
Background: Gabapentinoids (e.g., gabapentin, pregabalin) are frequently used off-label for pain and psychiatric conditions. Gabapentin alone rose from the seventh most prescribed medication in 2017 to the fourth most prescribed medication in the United States by January 2019. Gabapentinoid-associated somnolence (i.e. drowsiness and fatigue) has an...
Poster
Background: Gabapentin was approved in 1993 and has two narrowly defined FDA-approved indications. However, off-label gabapentin utilization is rising for a variety of conditions, most prominently for pain and psychiatric disorders. There are case reports of suicidal behavior associated with off-label gabapentin use in psychiatric disorders, but co...
Article
Full-text available
Use of medical marijuana is increasing in the United States and older adults are the fastest growing user group. There is little information about the characteristics and outcomes related to medical marijuana use. This study is a descriptive analysis of older adults (aged ≥50 years old) who were early adopters of a medical marijuana program in the...

Network

Cited By